TABLE 2

HPV Prevalence Among Females Aged 14 to 34 Years, According to Age Group, NHANES 2003–2006 and 2009–2012

Age Group/HPV TypePrevaccine Era 2003–2006 % (95% CI)Vaccine Era 2009–2012 % (95% CI)Comparison of Vaccine Era With Prevaccine Era
PR (95% CI)aPR (95% CI)
14–19 yn = 1363n = 736
 Any HPV32.9 (29.5–36.4)29.0 (24.5–33.9)0.88 (0.73–1.07)0.93 (0.79–1.09)
 Non-4vHPV31.2 (28.0–34.7)28.4 (24.0–33.2)0.91 (0.75–1.11)0.96 (0.82–1.14)
 Non-4vHPV HR20.7 (17.9–23.9)18.6 (14.7–23.4)0.90 (0.68–1.18)0.99 (0.79–1.26)
 HPV-31, -33, -454.3 (3.1–6.1)2.6a (1.2–5.5)0.59 (0.25–1.38)0.66 (0.27–1.59)
 HPV-31, -33, -45, -52, -58   8.4 (6.7–10.5)6.2 (4.1–9.3)0.74 (0.46–1.19)0.82 (0.53–1.28)
 4vHPV11.5 (9.2–14.4) 4.3 (2.7–6.8)0.37 (0.22–0.63)**0.36 (0.21–0.61)**
 HPV-16, -187.1 (5.8–8.7) 2.8 (1.6–4.7)0.39 (0.22–0.68)**0.37 (0.20–0.67)**
20–24 yn = 432n = 470
 Any HPV53.7 (46.0–61.3)57.9 (52.5–63.2)1.08 (0.91–1.28)1.02 (0.88–1.18)
 Non-4vHPV50.7 (43.6–57.9)56.1 (50.4–61.6)1.10 (0.93–1.32)1.05 (0.90–1.23)
 Non-4vHPV HR32.9 (26.8–39.6)36.8 (30.8–43.3)1.12 (0.87–1.45)1.11 (0.85–1.44)
 HPV-31, -33, -457.8 (5.0–12.0)5.4 (3.6–8.2)0.70 (0.38–1.27)0.85 (0.48–1.50)
 HPV-31, -33, -45, -52, -5816.5 (11.4–23.2)12.7 (8.6–18.2)0.77 (0.46–1.29)0.85 (0.51–1.41)
 4vHPV18.5 (14.9–22.7)12.1 (9.1–16.0)0.66 (0.46–0.93)*0.66 (0.47–0.93)*
 HPV-16, -1815.2 (11.7–19.5)10.5 (7.7–14.2)0.69 (0.47–1.03)0.66 (0.45–0.97)*
25–29 yn = 403n = 424
 Any HPV46.8 (42.9–50.7)49.1 (43.8–54.5)1.05 (0.92–1.20)1.06 (0.90–1.24)
 Non-4vHPV43.8 (39.0–48.8)47.5 (42.1–53.0)1.08 (0.92–1.27)1.09 (0.91–1.31)
 Non-4vHPV HR24.6 (19.1–31.0)28.1 (23.9–32.9)1.14 (0.86–1.53)1.09 (0.79–1.50)
 HPV-31, -33, -455.8 (3.7–9.0)6.2 (3.7–10.0)1.07 (0.55–2.08)1.27 (0.68–2.38)
 HPV-31, -33, -45, -52, -5810.8 (7.3–15.6)13.4 (10.1–17.6)1.25 (0.78–1.99)1.34 (0.81–2.21)
 4vHPV11.8 (8.8–15.5)11.7 (8.7–15.4)0.99 (0.66–1.48)1.04 (0.72–1.50)
 HPV-16, -188.1 (6.1–10.7) 9.9 (7.3–13.3)1.22 (0.81–1.85)1.17 (0.79–1.73)
30–34 yn = 389n = 428
 Any HPV47.9 (42.4–53.4)40.3 (34.7–46.1)0.84 (0.70–1.01)0.80 (0.66–0.98)*
 Non-4vHPV44.5 (39.2–50.0)37.9 (32.1–44.1)0.85 (0.70–1.04)0.83 (0.67–1.02)
 Non-4vHPV HR21.0 (15.6–27.6)21.6 (17.6–26.3)1.03 (0.73–1.46)0.98 (0.67–1.42)
 HPV-31, -33, -454.1a (2.2–7.5)4.2 (2.8–6.2)1.02 (0.48–2.14)0.85 (0.40–1.80)
 HPV-31, -33, -45, -52, -589.8 (7.1–13.4)7.5 (5.5–10.1)0.76 (0.49–1.18)0.58 (0.35–0.97)*
 4vHPV9.5 (6.8–13.1)8.0 (5.8–10.9)0.84 (0.53–1.32)0.77 (0.48–1.24)
  HPV-16, -187.6 (5.0–11.2)6.6 (4.5–9.5)0.87 (0.50–1.50)0.78 (0.45–1.36)
  • Data are for all females, including those who did not report having had sex. aPR was adjusted for race/ethnicity and lifetime and past year sex partners (14- to 19-year-old age group not adjusted for past year partners). Non-4vHPV high-risk (HR) includes types -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68. 4vHPV includes types -6, -11, -16, and -18. PR, prevalence ratio.

  • * P < .05; **P < .01 obtained by using the logistic regression model.

  • a RSE >30%.